Revenue, therapy area, R&D expenditure, and reach are among the critical segments of the global pharmaceutical industry. Mid-size pharmaceutical is among the three categories of the pharmaceutical industry. It emphasizes the development of generic drugs and the development of rare disease therapies. The mid-sized pharmaceutical companies have their revenue in the range of US$ 1 billion to US$ 10 billion. The increasing prevalence of chronic diseases, rapidly rising elderly population, and the surging number of products launches & approvals is expected to aid the mid-size pharmaceutical market growth.
DAIICHI SANKYO COMPANY LIMITED and Regeneron Pharmaceuticals, Inc – Notable Market Players in Mid-Size Pharmaceutical Market
Key factors that are driving the growth of this market are the growing prevalence of prevalence of chronic disorders and rising number of product launches and approvals are expected to drive the market during the forecast period. However, the cutthroat competition among market players hampers the mid-size pharmaceutical market growth.
The mid-size pharmaceutical market is majorly comprised of top players involving DAIICHI SANKYO COMPANY LIMITED, Eisai Co., Ltd., Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Alexion Pharmaceuticals, Inc., Mallinckrodt, Endo Pharmaceuticals Inc., Les Laboratories Servier, UCB S.A. among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the mid-size pharmaceutical market:
| Year | News |
| April-2022
|
Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc. announced a definitive agreement for Regeneron to acquire Checkmate for $10.50 per share of Checkmate common stock in an all-cash transaction. Checkmate’s entire stock value is estimated to be around $250 million in the proposed acquisition |
| May-2022 | Takeda and Daiichi Sankyo have announced that they would collaborate on a new research initiative to build a wearable device that will track lifestyle behaviours with Tohoku University and MICIN, a digital health and telemedicine company. The project will look into the practicality of tracking lifestyle habits over time as a model case for the development of personalized healthcare based on wearable tracking devices, with the purpose of fostering the launch and use of comparable platforms in Japan and elsewhere. Takeda and Daiichi Sankyo are hoping that the research initiative would lead to further innovative medical technology and pharmaceuticals being discovered. |
| May-2022
|
ToMMo, Daiichi Sankyo, Takeda, and MICIN have teamed up to conduct year-long research using a wearable tracking device. This collaborative study integrates objective sleep and physical activity assessments with data from an existing cohort study to drive innovative pharmaceutical research, such as medication development, toward the achievement of precision medicine and personalised healthcare. Wearable tracking devices that may be worn on the body like a wristwatch to collect biometric data on a daily and continuous basis are becoming more popular around the world, for both general and medical purposes. In general, wearable tracking devices include sensors that collect data such as heart rate and body movement (acceleration). |
| May-2022 | Sun Pharma including its subsidiaries and/or associate companies), announced that it has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic Mesalamine Extended-Release Capsules, 500 mg. The generic product approval is based on Pentasa Extended-Release Capsules, 500mg as a reference product. |
| May-2022 | Salix Pharmaceuticals, (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, announced seven posters on behalf of XIFAXAN (rifaximin), TRULANCE (plecanatide), and PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), will be shared at Digestive Disease Week (DDW) 2022, which is being held virtually and in-person in San Diego. XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN |
